Dept. of Psychiatry & Human Behavior
The Warren Alpert Medical School of Brown University
The Miriam Hospital
Centers for Behavioral and Preventive Medicine
Coro Building, Suite 500
One Hoppin Street
Providence, Rhode Island 02903
Phone: (401) 793-8180
Fax: (401) 793-8078
Kathleen Morrow, PhD, is an associate professor of psychiatry and human behavior at The Warren Alpert Medical School of Brown University and staff psychologist in the Centers for Behavioral and Preventive Medicine at The Miriam Hospital. She serves as faculty in the Lifespan/Tufts/Brown Centers for AIDS Research (CFAR) and as training faculty in the Center for Alcohol and Addiction Studies (CAAS). Her research interests focus on HIV and STD prevention, with a recent emphasis on the acceptability of experimental vaginal microbicides designed to provide woman-controlled HIV prevention options. She has been principal investigator on several NIH research studies, including an R01 designed to develop and evaluate instruments to measure factors related to microbicide use, and a R21/R33 mechanism that funds research within the NIH's Microbicide Innovation Program (MIP). In addition, she has been the Principal Investigator on a CDC funded Cooperative Agreement designing and evaluating an HIV/STD/hepatitis intervention for young men leaving an incarcerated setting. Morrow's research, conducted both domestically and internationally, incorporates traditional quantitative evaluation, qualitative methods, and mixed methodologies. Given her expertise in these methods, she mentors postdoctoral trainees and junior faculty, facilitating their ability to develop and evaluate interventions and measurement systems within their own research areas.
A Contextual Model of Microbicide Acceptability, NIMH
Kathleen M. Morrow, PhD, PI
The project aims to explore the acceptability of microbicides, topical vaginal products women will be able to use to prevent or reduce HIV transmission, by: 1) conducting secondary qualitative meta-analyses on data collected during clinical trials of candidate microbicides and other formative studies, 2) developing a pool of quantitative items that can be used to develop scales and indices of microbicide acceptability, 3) conducting evaluative work on the items such that a set of scales and/or items is produced for use in Phase III efficacy trials and further acceptability research. The project completed enrollment of 531 women from 4 states in the northeast US. Data are now being analyzed, with the goal of validating several scales for subsequent microbicide acceptability study use.
Buck, J.M., Morrow, K.M., Margolis, A., Eldridge, G., Sosman, J., Binson, D., MacGowan, R, Kacanek, D, Flanigan, TP, & The Project START Study Group. (in press). Hepatitis B vaccination in prison: The perspectives of formerly incarcerated men. Journal of Correctional Health Care.
El-Sadr, WM, Mayer, KH, Maslanowski, L, Hoesley, C, Justman, J, Gai, F,
Mauck, C, Absalon, J, Carballo-Dieguez, A, Morrow, K, Msse, B,
Soto-Torres, L & Kwiecien, A for the HIV Prevention Trials Network
(HPTN) 049 Protocol Team. (in press). Safety and Acceptability of
Cellulose Sulfate as a Vaginal Microbicide in HIV-infected Women. AIDS.
Dr. Morrow was the Chair of the Acceptability Substudy for this project
and is the only acceptability investigator in the author group.
Wolitski, R. for The Project START Study Group* (in press). The Effects of a Multi-Session Intervention on the Sexual Risk of Young Men Released from Prisons in 4 US States. American Journal of Public Health. *Morrow was the Principal Investigator for the Rhode Island site.
Mayer, KH, Maslankowski, LA, Gai, F, El-Sadr, WM, Justman, J, Kwiecien, A, Msse, B, Eshleman, SH, Hendrix, C, Morrow, K, Rooney, JF, Soto-Torres, L, & the HPTN 050 Protocol Team (2006). Safety and tolerability of Tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS, 20, 543-551.
Grinstead, O., Faigeles, B., Comfort, M., Seal, D., Nealey-Moore, J.,
Belcher, L., Morrow, K. and the Project Start Study Group.
(2005). HIV, STD, and hepatitis risk to primary female partners of men
being released from prison. Women and Health, 41, 63-80.
Sosman JM, MacGowan RJ, Margolis AD, Eldridge G, Flanigan T, Vardaman J, Fitzgerald C, Kacanek D, Binson D, Seal DW, and the Project START Study Group* (2005). The Feasibility of STD and Hepatitis Screening Among 18-29 Year Old Men Recently Released From Prison. International Journal of STD & AIDS; 16: 117-122. *Morrow was the Principal Investigator for the Rhode Island site.
Morrow, K., Costello, T. (2004). HIV, STD and Hepatitis
Prevention among Women in Methadone Maintenance: A Qualitative and
Quantitative Needs Assessment. AIDS Care, (16) 4, 426-433.
Seal, D., Belcher, L., Morrow, K., Eldridge, G., Binson, D., Kacanek, D., Margolis, A., McAuliffe, T., Simms, R. & The Project START Study Group (2004). A qualitative study of substance use and sexual behavior among 18- to 29- year old men while incarcerated in the United States. Health Education and Behavior, 31(6), 775-789.
Grinstead O, Seal DW, Wolitski R, Flanigan T, Fitzgerald C, Nealey-Moore
J, Askew J, and the Project START Study Group*. (2003). HIV and
STD testing in prisons: perspectives of in-prison service providers. AIDS
Education and Prevention, 15, 547-560.
*Morrow was the Principal Investigator for the Rhode
MacGowan, R.J., Margolis, A., Gaiter, J., Morrow, K., Zack, B., Askew, J., McAuliffe, T., Sosman, J.M., Eldridge, G., and the Project START Study Group. (2003). Predictors of risky sex of young men after release from prison. International Journal of STD and AIDS, 14, 519-523.
Mason, T.H., Foster, S.E., Finlinson, H.A., Morrow, K.M., Rosen, R., Vining-Bethea, S., Joanis, C.L., Hammet, T.M., Seage, G.R. (2003). Perspectives on vaginal microbicides among women with drug-related HIV risks in three cities in the U.S. and Puerto Rico. AIDS & Behavior, 7, 339-351.
Seal DW, Margolis AD, Sosman J, Kacanek D, Binson D, and the Project START Study Group* (2003). HIV and STD Risk Behavior among 18-25 Year Old Men Released From U.S. Prisons: Provider Perspectives. AIDS & Behavior, 7(2), 131-141. *Dr. Morrow was the Principal Investigator for the Rhode Island site.
Morrow, K., Rosen, R., Richter, L., Emans, A., Forbes, A., Day, J., Morar, N., Maslankowski, L., Profy, A.T., Kelly, C., Abdool Karim, S., & Mayer, K. (2003). The acceptability of an investigational vaginal microbicide, PRO 2000 Gel in the context of a Phase I clinical trial. Journal of Women's Health, 12(7), 655-666.
Morrow, K., Costello, T., & Boland, R. (2001). Understanding the psychosocial needs of HIV-positive women: A qualitative study. Psychosomatics, 42, 497-503.
Bentley, M., Morrow, K., Fullem, A., Chesney, M., Horton, S.,
Rosenberg, Z., & Mayer, K. (2000). Acceptability of a potential
vaginal microbicide, Buffergel, during a phase I safety trial among
low-risk women in Rhode Island. Family Planning Perspectives, 32(4),
Niaura, R., Shadel, W., Morrow, K., Flanigan, T., & Abrams, D. (2000). HIV, AIDS, and smoking cessation: The time is now. Journal of Clinical Infectious Diseases, 31(3), 808-12.
Morrow, K., & Allsworth, J. (2000). Sexual risk in lesbian and bisexual women. Journal of the Gay and Lesbian Medical Association, 4, 159-165.
Osowiecki, D., Cohen, R., Morrow, K., Flanigan, T., & Boland, R. (2000). Neurocognitive and psychological contributions to quality of life in HIV-1 infected women. AIDS, 14, 1327-1332